Does benztropine (anticholinergic) need to be stopped before restarting an antipsychotic?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Benztropine Discontinuation Before Restarting Antipsychotics

Benztropine does not need to be stopped before restarting an antipsychotic; in fact, anticholinergics like benztropine should not be used routinely or prophylactically at all, but only prescribed short-term if significant extrapyramidal symptoms develop after dose reduction or switching strategies have failed. 1

Evidence-Based Approach to Anticholinergic Use

Primary Guideline Recommendation

  • Anticholinergics should not be used routinely for preventing extrapyramidal side effects when starting or restarting antipsychotics 1
  • Short-term use may only be considered in individuals with significant extrapyramidal side effects when dose reduction and switching strategies have proven ineffective, or when these side effects are acute or severe 1

When to Use Benztropine with Antipsychotics

  • Prophylactic antiparkinsonian agents may be considered only in patients at high risk for acute dystonias (young age, male gender, high-potency agents) or those with a documented history of dystonic reactions 1
  • This is particularly relevant for patients whose compliance may be compromised by fear of side effects, such as those who are paranoid or distrust medication 1

Specific Populations Where Benztropine Should Be Avoided

  • In elderly patients with Alzheimer's disease receiving typical antipsychotics, avoid use of benztropine or trihexyphenidyl entirely 1
  • In patients with cognitive impairment, constipation, diabetes, diabetic neuropathy, xerophthalmia, or xerostomia, avoid antipsychotics with anticholinergic properties and their adjunctive anticholinergics 2

Reassessment Strategy

  • The need for antiparkinsonian agents should be reevaluated after the acute phase of treatment or if antipsychotic doses are lowered, as many patients no longer need them during long-term therapy 1
  • Only 14.2% of chronic schizophrenic patients withdrawn from benztropine experienced extrapyramidal symptoms severe enough to require resumption of therapy 3
  • Withdrawal of benztropine in chronic patients actually improved cognitive function, particularly attention and concentration 3

Clinical Algorithm for Restarting Antipsychotics

  1. Start the antipsychotic without benztropine unless the patient has a documented history of severe dystonic reactions 1
  2. Monitor closely for extrapyramidal symptoms during the first 4-6 weeks 1
  3. If extrapyramidal symptoms develop, first attempt dose reduction of the antipsychotic 1
  4. If dose reduction is not feasible, consider switching to an atypical antipsychotic with lower extrapyramidal risk 1
  5. Only add benztropine if symptoms persist despite these strategies or if symptoms are acute and severe (e.g., dystonia, laryngospasm) 1

Important Caveats

  • Benztropine itself can cause cognitive impairment, particularly deficits in attention and concentration, which may be mistaken for negative symptoms of schizophrenia 3
  • Anticholinergic agents do not consistently help akathisia; beta-blockers and benzodiazepines are more effective for this specific extrapyramidal symptom 1
  • If benztropine was being used chronically before the antipsychotic was stopped, consider discontinuing it rather than continuing it when restarting, as most patients do not require long-term anticholinergic therapy 1, 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Using antipsychotic agents in older patients.

The Journal of clinical psychiatry, 2004

Research

The withdrawal of benztropine mesylate in chronic schizophrenic patients.

The British journal of psychiatry : the journal of mental science, 1983

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.